Investigator Initiated Study - Asenapine Early Psychosis
Status:
Unknown status
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
We propose a use of a unique facility, the databank at the CNDV, to examine the impact of
switching subjects to asenapine in an open-label naturalistic setting. This offers the
following advantages: i) providing data on a particularly important population, i.e.,
subjects who are at the inception of treatment for a psychotic disorder and who are likely to
remain on a given drug on a long-term basis; ii) its inclusion in a rich clinical setting,
with a clinical team dedicated to provide innovative interventions; iii) its naturalistic
design, that will allow to obtain data that will be applicable to "real-life" clinical
settings; indeed, subjects who will be switched to asenapine within the current project are
those we would switch to this drug in our daily practice.
Phase:
Phase 4
Details
Lead Sponsor:
Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec